Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Korean Journal of MedicineOpen Access

Molecular Residual Disease Monitoring and Early Recurrence Prediction in Solid Tumors: Clinical Applications and Evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSung Hee Lim

Discussion

Loading...

Member takes

Overview

Review highlights liquid biopsy's prognostic value in colorectal and lung cancers, indicating MRD's role in adjuvant therapy decisions.

Key Points

  • Prognostic value of circulating tumor DNA aids early prediction of cancer recurrence, potentially improving patient outcomes.
  • Key findings from trials like DYNAMIC and TRACERx reveal liquid biopsy effectiveness in assessing molecular residual disease.
  • Analysis emphasizes the importance of solid tumors management through advanced liquid biopsy technologies to guide therapy decisions.
  • Ongoing advancements in precision oncology will likely establish molecular monitoring as a standard practice in cancer care.

Cite This Study

Sung Hee Lim (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e389https://doi.org/10.3904/kjm.2025.100.6.274
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges2025 · 1 citations
  2. 2Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies2025 · 3 citations
  3. 3Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers2025 · 6 citations
  4. 4Liquid biopsy – a promising and effective method for surveying non-small cell lung cancer minimal residual diseases and anti-cancer drug response after treatment2025
  5. 5Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers2025